thymidine has been researched along with Renal Insufficiency, Chronic in 5 studies
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We used serum creatinine-based equations (ie, Cockcroft-Gault, Modification of Diet in Renal Disease, and Chronic Kidney Disease Epidemiology Collaboration) to estimate GFR (eGFR) in adults with chronic hepatitis B virus infection and compensated liver disease who participated in a phase III, randomized, double-blind study comparing the efficacy and safety of telbivudine (600 mg/d) and lamivudine (100 mg/d) for 2 years (the GLOBE study) and in long-term extension studies (4-6 years), as well as in patients with decompensated cirrhosis (2 years)." | 9.19 | Telbivudine improves renal function in patients with chronic hepatitis B. ( Bosset, S; Buti, M; Deray, G; Di Bisceglie, A; Gane, EJ; Lai, CL; Liaw, YF; Lim, SG; Papatheodoridis, G; Rasenack, J; Samuel, D; Trylesinski, A; Uddin, A; Wang, Y, 2014) |
| "We used serum creatinine-based equations (ie, Cockcroft-Gault, Modification of Diet in Renal Disease, and Chronic Kidney Disease Epidemiology Collaboration) to estimate GFR (eGFR) in adults with chronic hepatitis B virus infection and compensated liver disease who participated in a phase III, randomized, double-blind study comparing the efficacy and safety of telbivudine (600 mg/d) and lamivudine (100 mg/d) for 2 years (the GLOBE study) and in long-term extension studies (4-6 years), as well as in patients with decompensated cirrhosis (2 years)." | 5.19 | Telbivudine improves renal function in patients with chronic hepatitis B. ( Bosset, S; Buti, M; Deray, G; Di Bisceglie, A; Gane, EJ; Lai, CL; Liaw, YF; Lim, SG; Papatheodoridis, G; Rasenack, J; Samuel, D; Trylesinski, A; Uddin, A; Wang, Y, 2014) |
| "The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (lamivudine, telbivudine, entecavir) or nucleotide (adefovir, tenofovir) analogues (NAs), but it may be complex and the information is scarce." | 4.90 | Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. ( Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014) |
| "A total of 546 consecutive cirrhotic patients treated with entecavir (n = 359), telbivudine (n = 104), or tenofovir (n = 83) for chronic hepatitis B were enrolled." | 3.85 | Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. ( Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH, 2017) |
| "Lamivudine was switched to telbivudine." | 1.42 | Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy. ( Akarca, US; Bademkiran, F; Duman, S; Ersoz, G; Gunsar, F; Karasu, Z; Kose, T; Ozutemiz, O; Sozbilen, M; Turan, I; Yapali, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gane, EJ | 1 |
| Deray, G | 1 |
| Liaw, YF | 1 |
| Lim, SG | 1 |
| Lai, CL | 1 |
| Rasenack, J | 1 |
| Wang, Y | 1 |
| Papatheodoridis, G | 2 |
| Di Bisceglie, A | 1 |
| Buti, M | 1 |
| Samuel, D | 1 |
| Uddin, A | 1 |
| Bosset, S | 1 |
| Trylesinski, A | 1 |
| Yapali, S | 2 |
| Lok, AS | 1 |
| Pipili, C | 1 |
| Cholongitas, E | 1 |
| Turan, I | 1 |
| Bademkiran, F | 1 |
| Kose, T | 1 |
| Duman, S | 1 |
| Sozbilen, M | 1 |
| Gunsar, F | 1 |
| Ersoz, G | 1 |
| Akarca, US | 1 |
| Ozutemiz, O | 1 |
| Karasu, Z | 1 |
| Tsai, MC | 1 |
| Chen, CH | 1 |
| Hu, TH | 1 |
| Lu, SN | 1 |
| Lee, CM | 1 |
| Wang, JH | 1 |
| Hung, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine[NCT02774837] | Phase 4 | 146 participants (Actual) | Interventional | 2016-04-30 | Active, not recruiting | ||
| The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.[NCT02347345] | Phase 4 | 34 participants (Actual) | Interventional | 2016-11-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Gene expression profiles in PBMC will be determined using RNA Seq (NCT02347345)
Timeframe: 24 weeks
| Intervention | RNA seq different from active IDU (Number) |
|---|---|
| baseline | |
| Healthy Volunteers | 12 |
Gene expression profiles in PBMC will be determined using RNA Seq (NCT02347345)
Timeframe: 24 weeks
| Intervention | RNA seq different from active IDU (Number) | |||
|---|---|---|---|---|
| baseline | 4 weeks | 12 weeks | 24 weeks | |
| Active Injection Drug Use (IDU) | 9 | 9 | 9 | 9 |
| Former Injection Drug Use (Former IDU) | 11 | 11 | 11 | 11 |
Marker of immune activation as measured by levels of soluble CD14. Note that the levels of sCD14 were only measured at baseline in the Healthy Volunteers group and therefore there are no data for weeks 4, 12, or 24 entered. (NCT02347345)
Timeframe: 24 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| baseline | |
| Healthy Volunteers | 1542 |
Marker of immune activation as measured by levels of soluble CD14. Note that the levels of sCD14 were only measured at baseline in the Healthy Volunteers group and therefore there are no data for weeks 4, 12, or 24 entered. (NCT02347345)
Timeframe: 24 weeks
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| baseline | week 4 | week 12 | week 24 | |
| Active Injection Drug Use (IDU) | 1986 | 2060 | 2036 | 1973 |
| Former Injection Drug Use (Former IDU) | 1918 | 1805 | 1782 | 1819 |
HCV RNA levels in plasma (IU/mL) (NCT02347345)
Timeframe: 24 weeks
| Intervention | HCV RNA copies/mL plasma (Mean) | ||
|---|---|---|---|
| baseline | week 12 | week 24 | |
| Active Injection Drug Use (IDU) | 7781148 | 0 | 0 |
| Former Injection Drug Use (Former IDU) | 2320026 | 0 | 0 |
1 review available for thymidine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organopho | 2014 |
1 trial available for thymidine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Telbivudine improves renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hepati | 2014 |
Telbivudine improves renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hepati | 2014 |
Telbivudine improves renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hepati | 2014 |
Telbivudine improves renal function in patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hepati | 2014 |
3 other studies available for thymidine and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Potential benefit of telbivudine on renal function does not outweigh its high rate of antiviral drug resistance and other adverse effects.
Topics: Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; Renal Insu | 2014 |
Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy.
Topics: Aged; Antiviral Agents; Diabetes Mellitus; Drug Substitution; End Stage Liver Disease; Female; Glome | 2015 |
Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Hum | 2017 |